The overall goal of this project is to improve the data analytic procedures associated with quantitative real-time polymerase chain reaction (Q-RT-PCR), with particular focus on measuring mRNA expression of molecular biomarkers and their association with colorectal cancer. Colorectal cancer is the third most common malignancy in the United States, and the third most common cause of death among cancer-related mortalities. While resection therapy is the main course of treatment for these patients, over 50% of patients presumed cured will recur within three to five years. It is hypothesized that these recurrences are actually undetected micrometastases. We propose to adapt Q-RT-PCR technology by changing the methods to quantify the amount of mRNA expression based on nonlinear models of the kinetic reaction obtained from Q-RT-PCR experiments. The current approach to quantitation does not make use of most of the data from the kinetic RT-PCR reaction, and the assumptions of the current model do not match the reality of the experiments. Thus, we also propose extensions of the error structure of these models to account for serial dilution of samples, heterogeneity across concentrations, and dependence of replicate samples. It is our hypothesis that improved measurement of the quantity of molecular biomarkers will offer more accurate prognostic information for colorectal cancer patients. Data from two NCI funded multi-center trials of guanylyl-cyclase-C (GCC) are available for these studies to demonstrate the clinical utility of our proposed methods. ? ?
| Hyslop, Terry; Waldman, Scott A (2013) Guanylyl cyclase C as a biomarker in colorectal cancer. Biomark Med 7:159-67 |
| Hyslop, Terry; Waldman, Scott A (2013) Molecular staging of node negative patients with colorectal cancer. J Cancer 4:193-9 |
| Hyslop, Terry; Weinberg, David S; Schulz, Stephanie et al. (2012) Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. J Surg Oncol 106:24-30 |
| Mejia, Alex; Schulz, Stephanie; Hyslop, Terry et al. (2012) Molecular staging individualizing cancer management. J Surg Oncol 105:468-74 |
| Hyslop, Terry; Weinberg, David S; Schulz, Stephanie et al. (2012) Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer 118:2532-40 |
| Zuzga, David S; Pelta-Heller, Joshua; Li, Peng et al. (2012) Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer. Int J Cancer 130:2539-48 |
| Gong, Jian P; Schulz, Stephanie; Hyslop, Terry et al. (2012) GUCY2C molecular staging personalizes colorectal cancer patient management. Biomark Med 6:339-48 |
| Hyslop, Terry; Weinberg, David S; Schulz, Stephanie et al. (2011) Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res 17:3293-303 |
| Waldman, Scott A; Terzic, Andre (2011) Clinical pharmacology at the core of translational science. Expert Rev Clin Pharmacol 4:303-5 |
| Mejia, Alex; Schulz, Stephanie; Hyslop, Terry et al. (2010) Molecular staging estimates occult tumor burden in colorectal cancer. Adv Clin Chem 52:19-39 |
Showing the most recent 10 out of 13 publications
